Transforming MS Care: Advanced Strategies in Multiple Sclerosis Management

Multiple sclerosis (MS) is a chronic, immune-mediated disease in which early, individualized disease-modifying therapy (DMT) can reduce disease activity, delay disability progression, and preserve quality of life. As therapeutic options expand—particularly multiple anti-CD20 therapies with different dosing schedules, administration routes, and safety considerations—clinicians must accurately interpret trial and real-world data, weigh risk–benefit trade-offs, and align recommendations with patient goals. Inconsistent application of evidence-based MS management guidelines and variability in monitoring practices can contribute to suboptimal therapeutic outcomes, especially in older and pediatric patients, whose physiological and social considerations may affect tolerability, adherence, and long-term disease control.In this CMEO BriefCase, expert faculty will walk learners through a real-world case, stopping for strategic discussions on the assessment of data on available anti-CD20 therapies to make appropriate recommendations for patients with MS, utilization of evidence-based guidelines for MS management to optimize treatment selection and monitor therapeutic outcomes, and the development of tailored MS treatment plans to address the unique physiological and social needs of older and pediatric patients.Learn More Here